Mirum hepatitis drug lowers virus levels in late-stage study
Brelovitug met the main goal in chronic hepatitis delta virus patients, with 56% and 45% response rates versus 0% in delayed treatment at 24 weeks.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.